Analysts expect Cartesian Therapeutics, Inc. to report revenue of 191,217.60 for Q3 26, against a range of 182,302.08 to 200,133.12. The most recent reported quarter, Q2 26, came in at 0.00, a 100.0% miss against the 170,036.99 consensus.
| Metric | Q2 24 | Q3 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 33.27 M | 387,000.00 | 1.10 M | 298,000.00 | 452,000.00 | 947,000.00 | 78,000.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 7.36 M | 1.40 M | 994,204.58 | 974,874.10 | 283,906.90 | 151,791.29 | 230,658.46 | 180,047.92 | 200,133.12 | 377,892.76 | 68,403.51 | 72,622.21 | -4.26 M | -1.29 M | 8.04 M | 6.75 M | ||||||||||
| Low Estimate | 6.59 M | 1.19 M | 887,003.92 | 841,288.10 | 265,345.46 | 131,516.11 | 196,353.60 | 160,026.06 | 182,302.08 | 346,851.24 | 61,783.99 | 67,145.55 | -4.71 M | -1.54 M | 6.77 M | 6.28 M | ||||||||||
| Consensus Estimate | 6.98 M | 1.29 M | 940,604.25 | 908,081.10 | 274,626.18 | 141,653.70 | 213,506.03 | 170,036.99 | 191,217.60 | 362,372.00 | 65,093.75 | 69,883.88 | -4.48 M | -1.41 M | 7.41 M | 6.52 M |
Analysts expect Cartesian Therapeutics, Inc. to report earnings per share of -0.96 for Q3 26, against a range of -1.03 to -0.89. The most recent reported quarter, Q2 26, came in at 0.46, a 150.0% beat against the -0.92 consensus.
| Metric | Q2 24 | Q3 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.54 | -1.13 | -0.68 | 0.50 | -1.38 | -3.46 | -1.46 | 0.46 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.81 | -0.80 | -0.69 | -0.72 | -0.86 | -0.83 | -0.83 | -0.89 | -0.89 | -1.12 | -0.99 | -0.95 | -1.63 | -1.35 | -0.62 | -0.44 | ||||||||||
| Low Estimate | -0.95 | -0.86 | -0.81 | -0.80 | -0.92 | -0.91 | -0.99 | -0.95 | -1.03 | -1.20 | -1.19 | -1.01 | -1.85 | -1.63 | -0.66 | -0.48 | ||||||||||
| Consensus Estimate | -0.88 | -0.83 | -0.75 | -0.76 | -0.89 | -0.87 | -0.91 | -0.92 | -0.96 | -1.16 | -1.09 | -0.98 | -1.74 | -1.49 | -0.64 | -0.46 |
Pull Wall Street consensus for Cartesian Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=RNAC&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "RNAC", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=RNAC&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();